Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | Director · Chief Executive Officer | August 17, 2026 | August 19, 2026 |
| CONMED CorpCNMD · Entity 4691 | Director | September 08, 2026 | September 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 57,590 |
Reported balance
After 2026-08-17 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-08-17 · Grant · Acquired 57,590 · Balance 57,590 F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F12: 19,197 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 19,196 restricted stock units vest on 8/17/2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 93,582 |
Reported balance
After 2026-08-17 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-08-17 · Grant · Acquired 93,582 · Balance 93,582 F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F13: 93,582 restricted stock units vest on 8/17/2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 8,544 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 8,544 F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10: 8,544 restricted stock units vest on 8/15/2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 23,569 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 23,569 F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11: 11,785 restricted stock units vest on 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028. |
| Common StockSEC Table I · non-derivative | Direct | 82,762 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 82,762 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.97 · Expires 2027-08-05 | Direct | 115,724 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 115,724 F1: Fully exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.46 · Expires 2028-08-06 | Direct | 25,944 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 25,944 F1: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $94.52 · Expires 2029-08-15 | Direct | 28,940 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 28,940 F1: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.61 · Expires 2030-08-15 | Direct | 1,492 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 1,492 F1: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.61 · Expires 2030-08-15 | Direct | 29,391 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 29,391 F2: Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.83 · Expires 2030-11-01 | Direct | 38,252 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 38,252 F3: Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.54 · Expires 2031-02-01 | Direct | 1,621 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 1,621 F1: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.54 · Expires 2031-02-01 | Direct | 51,890 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 51,890 F4: Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $74.91 · Expires 2034-08-15 | Direct | 69,061 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 69,061 F5: Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.60 · Expires 2035-08-15 | Direct | 90,441 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 90,441 F6: Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 51,261 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 51,261 F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F8: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 70,708 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 70,708 F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
Filing footnotes · ownership attribution and instrument terms
F1: Fully exercisable.
F2: Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026.
F3: Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027.
F4: Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028.
F5: Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028.
F6: Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F8: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F9: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F10: 8,544 restricted stock units vest on 8/15/2027.
F11: 11,785 restricted stock units vest on 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028.
F12: 19,197 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 19,196 restricted stock units vest on 8/17/2029.
F13: 93,582 restricted stock units vest on 8/17/2029.
CONMED Corp
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 500 |
Reported balance
After 2026-09-08 transaction · row 1
1 source rowRow 1 · 2026-09-08 · Exercise / conversion · Acquired 500 · Balance 500 |
| RSUs (Restricted Stock Units)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2035-09-08 | Direct | 0 |
Reported balance
After 2026-09-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-08 · Exercise / conversion · Disposed 500 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 05, 2020 Filed Aug 7, 2020 22:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 8,991 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000251 · edgar.xml · derivative · entry 12 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,991 Underlying: Common Stock · 8,991 shares Expires 2027-08-05 F9 · derivative.exercise_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 2,015 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000251 · edgar.xml · derivative · entry 11 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,015 Underlying: Common Stock · 2,015 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9 · derivative.exercise_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F9 · derivative.expiration_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 1,666 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000167 · edgar.xml · derivative · entry 3 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,667 Underlying: Common Stock · 1,666 shares Expires 2025-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: 1,667 restricted stock units vest on 5/1/2021. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 821 | $227.54 | $186,810.34 |
DisclosureSEC source: 0000914190-20-000167 · edgar.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,668 Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 1,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000914190-20-000167 · edgar.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:10 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 15,948 | $0.00 Strike: $190.41 | $0.00 |
DisclosureSEC source: 0000914190-19-000257 · edgar.xml · derivative · entry 10 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,948 Underlying: Common Stock · 15,948 shares Expires 2026-08-07 F8 · derivative.exercise_date: Options to purchase 3,987 shares vest on each of 8/7/2020, 8/7/2021, 8/7/2022 and 8/7/2023. Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:10 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 11,961 | $0.00 Strike: $190.41 | $0.00 |
DisclosureSEC source: 0000914190-19-000257 · edgar.xml · derivative · entry 9 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,961 Underlying: Common Stock · 11,961 shares Expires 2026-08-07 F7 · derivative.exercise_date: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:10 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 2,363 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-19-000257 · edgar.xml · derivative · entry 8 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,363 Underlying: Common Stock · 2,363 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F7 · derivative.exercise_date: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F7 · derivative.expiration_date: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| May 01, 2019 Filed May 2, 2019 20:18 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock · Derivative | 1,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-002478 · primarydocument.xml · derivative · entry 3 Kelderman Kim · CIK 0001739054 · President, Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,667 shares Expires 2025-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2019 Filed May 2, 2019 20:18 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 844 | $202.13 | $170,597.72 |
DisclosureSEC source: 0001562180-19-002478 · primarydocument.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · President, Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 823 Read SEC document |
| May 01, 2019 Filed May 2, 2019 20:18 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 1,667 | $202.13 | $336,950.71 |
DisclosureSEC source: 0001562180-19-002478 · primarydocument.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · President, Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2018 Filed Aug 10, 2018 20:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to buy) · Derivative | 9,033 | $0.00 Strike: $177.32 | $0.00 |
DisclosureSEC source: 0001562180-18-003561 · primarydocument.xml · derivative · entry 3 Kelderman Kim · CIK 0001739054 · President, Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,033 Underlying: Common Stock · 9,033 shares Expires 2025-08-08 F2 · derivative.exercise_date: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 08, 2018 Filed Aug 10, 2018 20:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to buy) · Derivative | 12,044 | $0.00 Strike: $177.32 | $0.00 |
DisclosureSEC source: 0001562180-18-003561 · primarydocument.xml · derivative · entry 2 Kelderman Kim · CIK 0001739054 · President, Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,044 Underlying: Common Stock · 12,044 shares Expires 2025-08-08 F3 · derivative.exercise_date: Vests 3,011 shares each on 8/8/2019, 8/8/2020, 8/8/2021, 8/8/2022 Read SEC document |
| August 08, 2018 Filed Aug 10, 2018 20:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 1,691 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003561 · primarydocument.xml · derivative · entry 1 Kelderman Kim · CIK 0001739054 · President, Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,691 Underlying: Common Stock · 1,691 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:22 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 7,348 | $0.00 Strike: $150.78 | $0.00 |
DisclosureSEC source: 0001562180-18-002166 · primarydocument.xml · derivative · entry 3 Kelderman Kim · CIK 0001739054 · President, Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 7,348 shares Expires 2025-05-01 F4 · derivative.exercise_date: 1,837 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022 Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:22 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 2,652 | $0.00 Strike: $150.78 | $0.00 |
DisclosureSEC source: 0001562180-18-002166 · primarydocument.xml · derivative · entry 2 Kelderman Kim · CIK 0001739054 · President, Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,652 Underlying: Common Stock · 2,652 shares Expires 2025-05-01 F3 · derivative.exercise_date: 663 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022 Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:22 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-002166 · primarydocument.xml · derivative · entry 1 Kelderman Kim · CIK 0001739054 · President, Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2025-05-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: Vests 1,667 on 5/1/2019, 1,666 shares on 5/1/2020 and 1,667 on 5/1/2021 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.